The FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older with

MedPage Today

New York

United States

FDA Approves First Menin Inhibitor for Acute Leukemia

Syndax Pharmaceuticals' Revuforj (revumenib) approved by FDA for relapsed acute leukemia with KMT2A gene translocation. Read more here.

Media Bias/Fact Check

Seeking Alpha

Syndax wins FDA approval for leukemia drug revumenib (SNDX:NASDAQ)

Ad Fontes Media

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – WALTHAM, MA, USA I November 15, 2024 I Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refr…

pipelinereview

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation - Pipelinereview

Syndax secures FDA approval for Revuforj, marking a breakthrough as the first menin inhibitor for KMT2A-rearranged acute leukemia, achieving 21% complete remission in trials.

stocktitan.net

Syndax's Revuforj Wins FDA Approval as First Menin Inhibitor for Acute Leukemia

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00 p.m. ET – WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ — Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first…

pressreach.com

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation - PressReach

Revumenib has been approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older.

onclive.com

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

The indication is for adult and pediatric patients 1 year and older with a lysine methyltransferase 2A gene translocation.

Pharmacy Times

FDA Approves Revumenib for the Treatment of Relapsed or Refractory Acute Leukemia

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.

targetedonc.com

FDA Approves Revumenib in KMT2A-Rearranged Acute Leukemia

The FDA has approved revumenib (Revuforj) for the treatment of patients with relapsed/refractory acute leukemia with a KMT2A translocation in adult and pediatric patients 1 year and older.

cancernetwork.com

FDA Approves Revumenib for Relapsed/Refractory KMT2A-Translocated Acute Leukemia

Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.

FDA Approves First Menin Inhibitor for Acute Leukemia

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics